next-generation CAR T-cell platforms

Current translational bottlenecks for next-generation CAR T-cell therapies include immunogenicity, regulatory complexity, and production logistics.

Translation of CAR T-cell therapy success from hematologic malignancies to solid tumors remains challenging because of antigen heterogeneity, limited tumor infiltration, immunosuppressive tumor microenvironments, and progressive T-cell exhaustion.

Next-generation CAR T-cell platforms integrate receptor architecture, intracellular signaling, and programmable control systems to enhance specificity, persistence, and safety.

Advances in next-generation CAR T-cell engineering position these therapies as programmable and adaptable immunotherapeutic platforms with potential to extend durable clinical benefit beyond hematologic cancers into solid tumors.